Bacterial Conjunctivitis Drugs Market to Expand at CAGR of 2.7%

Bacterial Conjunctivitis Drugs Market in U.S. to Reach US$439.8 mn by 2024; Patent Expirations Could Adversely Impact Growth According to a new market report published by Transparency Market Research “Bacterial Conjunctivitis Drugs Market - U.S. Industry Analysis, Pipeline Assessment, Size, Share, Growth, Trends and Forecast 2016 - 2024� the bacterial conjunctivitis drugs market in the U.S. was valued at US$473.3 mn in 2013 and is estimated to reach a market worth of US$439.8 mn in 2024, at a CAGR of 2.7% from 2012 to 2018 and (-3.73%) from 2018 to 2024.

Conjunctivitis is an inflammation of the conjunctiva - the clear membrane that covers the outermost layer of an eye and the inner surface of eyelids. Conjunctivitis is segmented into three major categories: infective (viral and bacterial), allergic, and irritant (chemical). Bacterial conjunctivitis is one of the most commonly observed eye problems across all age groups, generally caused by bacteria such as Staphylococcus aureus, Moraxella lacunata, Haemophilus influenza, and others (e.g.

Chlamydia trachomatis, Proteus mirabilis, etc.).

As reported by Healio (specialty medical news and journal publisher), approximately 5 million acute bacterial conjunctivitis

cases are reported in the U.S. each year. Thus, high prevalence of bacterial conjunctivitis in the country demands effective medications, thereby driving the growth of the bacterial conjunctivitis drugs market in the U.S. Browse Full Research Report on Bacterial Conjunctivitis Drugs Market: http://www.transparencymarketresearch.com/us-bacterialconjunctivitis-drugs-market.html However, despite the increasing incidence of bacterial conjunctivitis, the overall bacterial conjunctivitis market in the U.S. is likely to witness negative growth due to the patent expirations of major blockbuster drugs such as Vigamox, Moxeza, Zymaxid, and Besivance in the next few years.

Rise in ophthalmic bacterial infections is increasing the demand for antibacterial drugs in the U.S. According to a clinical study conducted by the scientists Amir A. Azari and Neal P. Barney, published in the Journal of the American Medical Association (JAMA) in 2013, bacterial conjunctivitis accounts for over 50% of the conjunctivitis cases in the U.S. It also quoted that the incidence of bacterial conjunctivitis was estimated to be 135 in 10,000 in a single study. These statistics indicate that the U.S. is witnessing high incidence of bacterial

conjunctivitis, hence leading to increased demand for bacterial conjunctivitis drugs in the country.

Fluoroquinolones, aminoglycosides, macrolides and other antibacterials such as bacitracin, doxycycline, and ceftriaxone collectively form the bacterial conjunctivitis market; among which fluoroquinolones dominate the bacterial conjunctivitis drugs market in the U.S. with a share of more than 70% in 2013.

Fluoroquinolones are more widely prescribed as compared to other antibiotic drug classes for the treatment of bacterial conjunctivitis across the U.S. due to their higher efficacy against antibiotic-resistant bacterial strains and broad spectrum activity.

The growing awareness about healthcare among people, together with their rising disposable income and the availability of advanced healthcare devices, is expected to boost this market segment remarkably in the coming years, states the report.

On the regional basis, the study has segmented the global healthcare mobility solutions market into North America, Asia Pacific, Europe, and the Rest of the World. North America emerged as the largest regional market for healthcare mobility

solutions in 2014 and was closely followed by Asia Pacific and Europe. Analysts expect this regional market to maintain its dominance throughout the forecast period.

Asia Pacific is also projected to witness a healthy rise over the next few years, owing to the infrastructural growth in the medical and healthcare industry in this region, notes the study.

Cisco Systems Inc., McKesson Corp., Zebra Technologies Corp., AirStrip Technologies Inc., AT&T Inc., Omron Corp., SAP SE, Cerner Corp., Koninklijke Philips N.V., and Oracle Corp. are the major enterprises functional into the global healthcare mobility solutions market, states the research report.

Browse Full Press Release on Bacterial Conjunctivitis Drugs Market: Press Release

About Us Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data

sources and various tools and techniques to gather and analyze information.

TMR’s data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.

Contact Us Transparency Market Research State Tower, 90 State Street, Suite 700, Albany NY - 12207 United States USA - Canada Toll Free: 866-552-3453 Email: sales@transparencymarketresearch.com Website: http://www.transparencymarketresearch.com